26
Participants
Start Date
March 3, 2017
Primary Completion Date
December 31, 2017
Study Completion Date
December 3, 2018
S95005
The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
Russian Cancer Research Center n.a. NN Blokhin (RCRC), Clinical Pharmacology and Chemotherapy department, Moscow
Saint Petersburg Clinical Scientific-Practical Center of Special Medical Care (Oncology Center), Saint Petersburg
ADIR, a Servier Group company
INDUSTRY
Institut de Recherches Internationales Servier
OTHER